# Medicinova Inc: overview MNOV · Nasdaq · CIK 1226616 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mnov.md) · [Financials](/companies/mnov/financials.md) · [Filings](/companies/mnov/filings.md) · [Insiders](/companies/mnov/insiders.md) Latest reported revenue: [$458.4k](/filings/0001193125-26-349323.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-349323). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | [135](/filings/0001193125-26-349323.md) | [123](/filings/0001193125-25-277779.md) | [152 d](/filings/0001193125-26-100432.md) | [187](/filings/0001193125-26-224066.md) | [458](/filings/0001193125-26-349323.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(2679.9%)](/filings/0001193125-26-349323.md) | [(2741.7%)](/filings/0001193125-25-277779.md) | [(2038.0%) d](/filings/0001193125-26-100432.md) | [(1516.6%)](/filings/0001193125-26-224066.md) | [(554.3%)](/filings/0001193125-26-349323.md) | | Net margin | % | not reported | not reported | not reported | [(2437.7%)](/filings/0001193125-26-349323.md) | [(2473.6%)](/filings/0001193125-25-277779.md) | [(1846.8%) d](/filings/0001193125-26-100432.md) | [(1383.1%)](/filings/0001193125-26-349323.md) | [(504.8%)](/filings/0001193125-26-349323.md) | | Diluted EPS | $ per share | [(0.06)](/filings/0001193125-25-277779.md) | not reported | [(0.06)](/filings/0001193125-26-224066.md) | [(0.07)](/filings/0001193125-26-349323.md) | [(0.06)](/filings/0001193125-25-277779.md) | not reported | [(0.05)](/filings/0001193125-26-224066.md) | [(0.05)](/filings/0001193125-26-349323.md) | | Free cash flow | $k | [(2,032) d](/filings/0001193125-25-277779.md) | [(1,932) d](/filings/0001193125-26-100432.md) | [(3,784)](/filings/0001193125-26-224066.md) | [(2,306) d](/filings/0001193125-26-349323.md) | [(1,706) d](/filings/0001193125-25-277779.md) | [(2,017) d](/filings/0001193125-26-100432.md) | [(3,481)](/filings/0001193125-26-224066.md) | [(1,920) d](/filings/0001193125-26-349323.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.0](/filings/0000950170-23-010297.md) | not reported | [1.0](/filings/0000950170-25-023301.md) | not reported | [0.4](/filings/0001193125-26-100432.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(253.0%)](/filings/0000950170-23-010297.md) | not reported | [(990.0%)](/filings/0000950170-25-023301.md) | not reported | [(3242.5%)](/filings/0001193125-26-100432.md) | | Net margin | % | [(251.0%)](/filings/0000950170-23-010297.md) | not reported | [(857.2%)](/filings/0000950170-25-023301.md) | not reported | [(2928.8%)](/filings/0001193125-26-100432.md) | | Diluted EPS | $ per share | [(0.21)](/filings/0000950170-23-010297.md) | [(0.29)](/filings/0000950170-24-015920.md) | [(0.17)](/filings/0000950170-25-023301.md) | [(0.23)](/filings/0001193125-26-100432.md) | [(0.24)](/filings/0001193125-26-100432.md) | | Free cash flow | $m | [(9.4)](/filings/0000950170-23-010297.md) | [(12.9)](/filings/0000950170-24-015920.md) | [(7.5)](/filings/0000950170-25-023301.md) | [(10.6)](/filings/0001193125-26-100432.md) | [(9.8)](/filings/0001193125-26-100432.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mnov/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Essex Woodlands Management, Inc.](/funds/1542339.md) | 2026-06-30 | $1.5m | 1,105,941 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $992.8k | 752,091 | | Added +46,137 | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $839.1k | 635,715 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $803.9k | 609,052 | | Reduced −1,987 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $712.1k | 539,312 | | Reduced −4,531 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $373.0k | 282,608 | | Added +1,987 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $293.3k | 222,200 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $271.1k | 205,400 | | Added +15,500 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $255.7k | 193,698 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $189.6k | 143,665 | | Added +10,502 | ## Recent filings [All 646 filings](/companies/mnov/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 17:00 ET | [SCHEDULE 13D/A](/filings/0001213900-26-104738.md) | Ownership report, active investor, amended | 0001213900-26-104738 | | 2026-09-28 | 16:05 ET | [8-K](/filings/0001193125-26-405318.md) | 1.01 Entry into a material agreement | 0001193125-26-405318 | | 2026-09-02 | 07:30 ET | [8-K](/filings/0001193125-26-379348.md) | 1.02 Termination of a material agreement | 0001193125-26-379348 | | 2026-08-19 | 07:30 ET | [8-K](/filings/0001193125-26-356146.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-356146 | | 2026-08-13 | 16:30 ET | [10-Q](/filings/0001193125-26-349323.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349323 | | 2026-06-24 | 16:38 ET | [8-K](/filings/0001193125-26-281171.md) | 5.07 Shareholder vote results | 0001193125-26-281171 | | 2026-05-14 | 16:15 ET | [10-Q](/filings/0001193125-26-224066.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224066 | | 2026-04-29 | 16:26 ET | [DEF 14A](/filings/0001193125-26-191866.md) | Proxy statement, period 2026-06-23 | 0001193125-26-191866 | | 2026-03-10 | 17:15 ET | [10-K](/filings/0001193125-26-100432.md) | Annual report, period 2025-12-31 | 0001193125-26-100432 | | 2026-02-20 | 06:25 ET | [8-K](/filings/0001193125-26-060232.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-060232 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-100432.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d27a411b-6c1e-4254-a581-d350c8f6b489) ## About the filer - CIK: 1226616 - Tickers: MNOV - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 17:11 ET. No prices; not investment advice.